[{"id":"0a6aefb7-2166-498d-888e-ed54ef581ee3","acronym":"","url":"https://clinicaltrials.gov/study/NCT00792948","created_at":"2021-01-18T03:00:33.783Z","updated_at":"2025-02-25T12:25:29.112Z","phase":"Phase 2","brief_title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT00792948","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR • CD22 • CD5 • CD79A • MME • CD7 • ANPEP • MPO","pipe":"","alterations":" ","tags":["ABL1 • BCR • CD22 • CD5 • CD79A • MME • CD7 • ANPEP • MPO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • sirolimus • leucovorin calcium • Hemady (dexamethasone tablets) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 97","initiation":"Initiation: 09/01/2009","start_date":" 09/01/2009","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 01/06/2026","study_completion_date":" 01/06/2026","last_update_posted":"2025-02-24"},{"id":"a01c1d5f-e2a9-42b3-82b6-70a6e6b04112","acronym":"AALL1131","url":"https://clinicaltrials.gov/study/NCT02883049","created_at":"2021-01-18T14:09:12.849Z","updated_at":"2025-02-25T13:39:22.892Z","phase":"Phase 3","brief_title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","source_id_and_acronym":"NCT02883049 - AALL1131","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR • RUNX1 • KMT2A • ETV6","pipe":" | ","alterations":" MLL rearrangement","tags":["ABL1 • BCR • RUNX1 • KMT2A • ETV6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • prednisone • daunorubicin • clofarabine • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 5949","initiation":"Initiation: 02/29/2012","start_date":" 02/29/2012","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 10/03/2025","study_completion_date":" 10/03/2025","last_update_posted":"2025-02-21"},{"id":"39a3ce34-fc3f-4772-a312-5b10b9a2eacf","acronym":"","url":"https://clinicaltrials.gov/study/NCT00390793","created_at":"2022-04-24T08:54:27.800Z","updated_at":"2025-02-25T14:06:37.175Z","phase":"Phase 2","brief_title":"Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.","source_id_and_acronym":"NCT00390793","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • prednisone • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Completed","enrollment":" Enrollment 107","initiation":"Initiation: 09/28/2006","start_date":" 09/28/2006","primary_txt":" Primary completion: 02/02/2024","primary_completion_date":" 02/02/2024","study_txt":" Completion: 02/02/2024","study_completion_date":" 02/02/2024","last_update_posted":"2025-02-17"},{"id":"d6077c21-17bb-4f1e-9fd6-5e8d472b76ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT03854903","created_at":"2021-01-18T19:01:32.210Z","updated_at":"2025-02-25T16:37:21.932Z","phase":"Phase 1","brief_title":"WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor","source_id_and_acronym":"NCT03854903","lead_sponsor":"Georgetown University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • fulvestrant • bosutinib"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 04/01/2019","start_date":" 04/01/2019","primary_txt":" Primary completion: 11/01/2023","primary_completion_date":" 11/01/2023","study_txt":" Completion: 01/09/2025","study_completion_date":" 01/09/2025","last_update_posted":"2025-02-06"},{"id":"0adc2fbc-6b3e-4f34-8de8-ac2947fe1dfb","acronym":"","url":"https://clinicaltrials.gov/study/NCT00070499","created_at":"2021-01-18T00:10:44.565Z","updated_at":"2025-02-25T16:21:43.510Z","phase":"Phase 2","brief_title":"Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia","source_id_and_acronym":"NCT00070499","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 406","initiation":"Initiation: 08/15/2004","start_date":" 08/15/2004","primary_txt":" Primary completion: 11/01/2010","primary_completion_date":" 11/01/2010","study_txt":" Completion: 02/22/2025","study_completion_date":" 02/22/2025","last_update_posted":"2024-12-27"},{"id":"4d2a06b2-d858-435f-8f2c-4ebc80c32731","acronym":"","url":"https://clinicaltrials.gov/study/NCT00254423","created_at":"2021-01-18T00:51:48.619Z","updated_at":"2024-07-02T16:34:26.966Z","phase":"Phase 2","brief_title":"Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia","source_id_and_acronym":"NCT00254423","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ABL1 • BCR • IFNA1","pipe":"","alterations":" ","tags":["ABL1 • BCR • IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 11/08/2005","start_date":" 11/08/2005","primary_txt":" Primary completion: 11/30/2024","primary_completion_date":" 11/30/2024","study_txt":" Completion: 11/30/2024","study_completion_date":" 11/30/2024","last_update_posted":"2024-06-12"},{"id":"d089607a-1031-4001-af05-f61c61e55845","acronym":"","url":"https://clinicaltrials.gov/study/NCT02013648","created_at":"2021-01-18T09:12:24.696Z","updated_at":"2024-07-02T16:35:17.930Z","phase":"Phase 3","brief_title":"Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™)","source_id_and_acronym":"NCT02013648","lead_sponsor":"University of Ulm","biomarkers":" RUNX1 • RUNX1T1","pipe":" | ","alterations":" RUNX1-RUNX1T1 fusion • CBFB-MYH11 fusion","tags":["RUNX1 • RUNX1T1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RUNX1-RUNX1T1 fusion • CBFB-MYH11 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • daunorubicin • idarubicin hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 204","initiation":"Initiation: 07/01/2014","start_date":" 07/01/2014","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 02/01/2024","study_completion_date":" 02/01/2024","last_update_posted":"2024-02-23"},{"id":"0170dcd4-c22d-42e8-a253-3a55399779ea","acronym":"AAML1921","url":"https://clinicaltrials.gov/study/NCT04258943","created_at":"2023-12-14T16:16:46.995Z","updated_at":"2025-02-25T16:25:40.949Z","phase":"Phase 1/2","brief_title":"Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia","source_id_and_acronym":"NCT04258943 - AAML1921","lead_sponsor":"Children's Oncology Group","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bosutinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 04/06/2020","start_date":" 04/06/2020","primary_txt":" Primary completion: 07/01/2028","primary_completion_date":" 07/01/2028","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2024-02-22"},{"id":"7ad2d769-2235-480c-af61-d1fa70b9f998","acronym":"","url":"https://clinicaltrials.gov/study/NCT00255346","created_at":"2021-01-18T00:51:58.980Z","updated_at":"2025-02-25T14:23:55.411Z","phase":"Phase 2","brief_title":"Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)","source_id_and_acronym":"NCT00255346","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KIT","pipe":" | ","alterations":" KIT positive","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 11/15/2005","start_date":" 11/15/2005","primary_txt":" Primary completion: 03/03/2017","primary_completion_date":" 03/03/2017","study_txt":" Completion: 03/03/2017","study_completion_date":" 03/03/2017","last_update_posted":"2023-12-18"},{"id":"a976d708-4f7e-45aa-b0eb-eedbc6a94f74","acronym":"TOKIN","url":"https://clinicaltrials.gov/study/NCT04626024","created_at":"2021-01-19T20:35:32.623Z","updated_at":"2024-07-02T16:35:26.331Z","phase":"Phase 2","brief_title":"Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population","source_id_and_acronym":"NCT04626024 - TOKIN","lead_sponsor":"Baylor College of Medicine","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib • nilotinib • bosutinib"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 12/22/2020","start_date":" 12/22/2020","primary_txt":" Primary completion: 11/15/2025","primary_completion_date":" 11/15/2025","study_txt":" Completion: 11/15/2025","study_completion_date":" 11/15/2025","last_update_posted":"2023-12-13"},{"id":"d4088676-34af-47b3-9b35-79e3fba11bee","acronym":"","url":"https://clinicaltrials.gov/study/NCT03193281","created_at":"2021-01-18T15:44:28.970Z","updated_at":"2024-07-02T16:35:27.695Z","phase":"Phase 2","brief_title":"KISS Study: Kinase Inhibition With Sprycel Start up","source_id_and_acronym":"NCT03193281","lead_sponsor":"University of Auckland, New Zealand","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 91","initiation":"Initiation: 07/17/2017","start_date":" 07/17/2017","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-11-29"},{"id":"5a3f91fc-1205-487d-92df-2b35d3f75bbe","acronym":"SHIELD-1","url":"https://clinicaltrials.gov/study/NCT03993873","created_at":"2021-01-18T19:38:12.132Z","updated_at":"2024-07-02T16:35:28.600Z","phase":"Phase 1/2","brief_title":"Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET","source_id_and_acronym":"NCT03993873 - SHIELD-1","lead_sponsor":"Turning Point Therapeutics, Inc.","biomarkers":" MET","pipe":" | ","alterations":" MET amplification • MET exon 14 mutation • MET mutation • MET fusion","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET exon 14 mutation • MET mutation • MET fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e elzovantinib (TPX-0022)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 09/21/2019","start_date":" 09/21/2019","primary_txt":" Primary completion: 03/02/2025","primary_completion_date":" 03/02/2025","study_txt":" Completion: 03/02/2025","study_completion_date":" 03/02/2025","last_update_posted":"2023-11-20"},{"id":"9805af40-e9ce-41b8-afa1-e5083a1435ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT02546375","created_at":"2021-01-18T12:19:07.644Z","updated_at":"2024-07-02T16:35:34.983Z","phase":"","brief_title":"A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands","source_id_and_acronym":"NCT02546375","lead_sponsor":"Pfizer","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bosutinib"],"overall_status":"Completed","enrollment":" Enrollment 87","initiation":"Initiation: 07/15/2015","start_date":" 07/15/2015","primary_txt":" Primary completion: 01/16/2017","primary_completion_date":" 01/16/2017","study_txt":" Completion: 01/16/2017","study_completion_date":" 01/16/2017","last_update_posted":"2023-10-03"},{"id":"13942605-9bf5-41a2-a7c2-5c5e7a8f8689","acronym":"","url":"https://clinicaltrials.gov/study/NCT03625388","created_at":"2021-01-18T17:48:36.247Z","updated_at":"2024-07-02T16:35:36.010Z","phase":"Phase 2","brief_title":"Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia","source_id_and_acronym":"NCT03625388","lead_sponsor":"Hikma Pharmaceuticals LLC","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib"],"overall_status":"Completed","enrollment":" Enrollment 56","initiation":"Initiation: 11/05/2018","start_date":" 11/05/2018","primary_txt":" Primary completion: 07/22/2023","primary_completion_date":" 07/22/2023","study_txt":" Completion: 07/22/2023","study_completion_date":" 07/22/2023","last_update_posted":"2023-09-22"},{"id":"ec9ebcd5-07dc-44c4-84f3-b2f26c471cab","acronym":"","url":"https://clinicaltrials.gov/study/NCT00777036","created_at":"2022-04-24T08:54:50.612Z","updated_at":"2024-07-02T16:35:37.250Z","phase":"Phase 2","brief_title":"A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib","source_id_and_acronym":"NCT00777036","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 03/20/2009","start_date":" 03/20/2009","primary_txt":" Primary completion: 09/01/2016","primary_completion_date":" 09/01/2016","study_txt":" Completion: 12/07/2029","study_completion_date":" 12/07/2029","last_update_posted":"2023-09-13"},{"id":"695c1a45-9603-4f8e-b6ce-75995a62ee90","acronym":"","url":"https://clinicaltrials.gov/study/NCT02311998","created_at":"2021-01-17T18:01:29.030Z","updated_at":"2024-07-02T16:35:42.833Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML","source_id_and_acronym":"NCT02311998","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ABL1 • BCR • CD22","pipe":"","alterations":" ","tags":["ABL1 • BCR • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bosutinib • Besponsa (inotuzumab ozogamicin)"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 04/16/2015","start_date":" 04/16/2015","primary_txt":" Primary completion: 03/23/2022","primary_completion_date":" 03/23/2022","study_txt":" Completion: 03/23/2022","study_completion_date":" 03/23/2022","last_update_posted":"2023-07-17"},{"id":"b23fd882-ff28-4564-bc15-fe532fcc31ca","acronym":"","url":"https://clinicaltrials.gov/study/NCT00700882","created_at":"2021-01-17T17:21:43.588Z","updated_at":"2024-07-02T16:35:44.187Z","phase":"Phase 2","brief_title":"Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery","source_id_and_acronym":"NCT00700882","lead_sponsor":"Eastern Cooperative Oncology Group","biomarkers":" KIT","pipe":" | ","alterations":" KIT mutation • KIT positive • KIT amplification","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT positive • KIT amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib"],"overall_status":"Completed","enrollment":" Enrollment 81","initiation":"Initiation: 07/02/2009","start_date":" 07/02/2009","primary_txt":" Primary completion: 05/06/2016","primary_completion_date":" 05/06/2016","study_txt":" Completion: 12/28/2020","study_completion_date":" 12/28/2020","last_update_posted":"2023-06-30"},{"id":"d04e0b2e-50d8-4bda-a7cf-087faf85938c","acronym":"DASCERN","url":"https://clinicaltrials.gov/study/NCT01593254","created_at":"2022-04-24T08:55:47.439Z","updated_at":"2024-07-02T16:35:45.286Z","phase":"Phase 2b","brief_title":"Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib","source_id_and_acronym":"NCT01593254 - DASCERN","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib"],"overall_status":"Completed","enrollment":" Enrollment 262","initiation":"Initiation: 09/12/2012","start_date":" 09/12/2012","primary_txt":" Primary completion: 11/08/2017","primary_completion_date":" 11/08/2017","study_txt":" Completion: 04/12/2022","study_completion_date":" 04/12/2022","last_update_posted":"2023-06-22"},{"id":"d94efaf1-e651-4f75-b178-3ccd46b27720","acronym":"DasaHIT","url":"https://clinicaltrials.gov/study/NCT02890784","created_at":"2022-04-24T08:57:55.150Z","updated_at":"2024-07-02T16:35:48.419Z","phase":"Phase 3","brief_title":"Dasatinib Holiday for Improved Tolerability","source_id_and_acronym":"NCT02890784 - DasaHIT","lead_sponsor":"University of Jena","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib"],"overall_status":"Completed","enrollment":" Enrollment 291","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 03/31/2023","primary_completion_date":" 03/31/2023","study_txt":" Completion: 03/31/2023","study_completion_date":" 03/31/2023","last_update_posted":"2023-05-10"},{"id":"51b0af63-00ed-4f95-8818-056a9fc2dad9","acronym":"BosuPeg","url":"https://clinicaltrials.gov/study/NCT03831776","created_at":"2022-04-24T08:59:51.579Z","updated_at":"2024-07-02T16:35:50.176Z","phase":"Phase 2","brief_title":"Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis","source_id_and_acronym":"NCT03831776 - BosuPeg","lead_sponsor":"St. Olavs Hospital","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bosutinib"],"overall_status":"Recruiting","enrollment":" Enrollment 212","initiation":"Initiation: 03/25/2019","start_date":" 03/25/2019","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 03/01/2028","study_completion_date":" 03/01/2028","last_update_posted":"2023-04-19"},{"id":"423e48f4-b2d2-484f-9077-f6c1de7d1e1a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02269267","created_at":"2022-04-24T08:56:57.764Z","updated_at":"2024-07-02T16:35:54.161Z","phase":"Phase 2","brief_title":"The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)","source_id_and_acronym":"NCT02269267","lead_sponsor":"Medical College of Wisconsin","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib • bosutinib"],"overall_status":"Completed","enrollment":" Enrollment 173","initiation":"Initiation: 12/18/2014","start_date":" 12/18/2014","primary_txt":" Primary completion: 04/06/2021","primary_completion_date":" 04/06/2021","study_txt":" Completion: 04/06/2022","study_completion_date":" 04/06/2022","last_update_posted":"2023-03-03"},{"id":"344dd84f-cbb2-4195-9057-7e6bb67aba39","acronym":"","url":"https://clinicaltrials.gov/study/NCT01238211","created_at":"2021-01-18T04:59:02.957Z","updated_at":"2024-07-02T16:35:54.402Z","phase":"Phase 2","brief_title":"Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","source_id_and_acronym":"NCT01238211","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RUNX1 • RUNX1T1","pipe":" | ","alterations":" RUNX1-RUNX1T1 fusion • CBFB-MYH11 fusion","tags":["RUNX1 • RUNX1T1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RUNX1-RUNX1T1 fusion • CBFB-MYH11 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Completed","enrollment":" Enrollment 61","initiation":"Initiation: 12/14/2010","start_date":" 12/14/2010","primary_txt":" Primary completion: 07/01/2013","primary_completion_date":" 07/01/2013","study_txt":" Completion: 03/15/2021","study_completion_date":" 03/15/2021","last_update_posted":"2023-03-01"},{"id":"3803238c-6897-4792-8192-1db65c7b3b43","acronym":"BEST","url":"https://clinicaltrials.gov/study/NCT02810990","created_at":"2021-01-18T13:47:10.028Z","updated_at":"2024-07-02T16:35:56.483Z","phase":"Phase 2","brief_title":"Bosutinib in Elderly Chronic Myeloid Leukemia","source_id_and_acronym":"NCT02810990 - BEST","lead_sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" BCR-ABL1 mutation","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bosutinib"],"overall_status":"Completed","enrollment":" Enrollment 65","initiation":"Initiation: 11/17/2016","start_date":" 11/17/2016","primary_txt":" Primary completion: 04/30/2020","primary_completion_date":" 04/30/2020","study_txt":" Completion: 06/22/2022","study_completion_date":" 06/22/2022","last_update_posted":"2023-02-03"},{"id":"e6a4679a-3426-425a-a0da-b8e775fb9844","acronym":"","url":"https://clinicaltrials.gov/study/NCT05682924","created_at":"2023-01-12T15:02:34.059Z","updated_at":"2024-07-02T16:35:57.708Z","phase":"","brief_title":"Condition Vasoregulation Function Endothelium in Patients With CML Getting TKI II Generation Bosutinib","source_id_and_acronym":"NCT05682924","lead_sponsor":"Samara State Medical University","biomarkers":" VEGFA","pipe":"","alterations":" ","tags":["VEGFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bosutinib"],"overall_status":"Recruiting","enrollment":" Enrollment 105","initiation":"Initiation: 10/01/2022","start_date":" 10/01/2022","primary_txt":" Primary completion: 05/01/2023","primary_completion_date":" 05/01/2023","study_txt":" Completion: 05/15/2023","study_completion_date":" 05/15/2023","last_update_posted":"2023-01-12"}]